A B S T R A C T Studies were carried out to compare the effects of parathyroid extract (PTE) on serum and urinary calcium (Ca) and phosphorus (P), serum 25-hydroxyvitamin D (25-OHD), serum 24,25-dihydroxyvitamin D (24,25(OH)2D), serum la,25-dihydroxyvitamin D (la,25(OH)2D), and urinary cyclic AMP in two normal subjects, two patients with hypoparathyroidism (HP) and six patients with pseudohypoparathyroidism (PHP), some of whom were on suboptimal treatment with vitamin D. Two of the patients with PHP were studied while on long-term treatment with la,25-(OH)2D3. Before PTE, serum la,25(OH)2D was at the lower limit ofnormal in one patient and was abnormally low in the other five patients. None ofthese individuals was on treatment with la,25(OH)2D3. Serum 25-OHD and 24,25(OH)2D were either increased or at the upper limit ofnormal in the patients given vitamin D and were normal in the other patients. PTE lowered the serum P and increased the serum la,25(OH)2D, serum and urinary Ca, urinary P, and urinary cyclic AMP in the normal subjects and patients with HP. In individual studies, changes in serum la,25(OH)2D and serum Ca occurred in parallel before, during, and after PTE. In contrast, PTE had very little effect in the patients with PHP. Whereas there were highly significant positive correlations between serum 1a,25(OH)2D and serum Ca, and highly significant negative correlations between serum P and serum la,25(OH)2D in each of the normal subjects and patients with HP, there were significant correlations in only one of the patients with PHP. An increase in serum Ca in response to PTE was observed in one ofthe two patients with PHP who were on long-term treatment with la,25(OH)2D3. In these individuals, PTE produced only slight increases in serum lac,25(OH)2D. Serum 25-OHD and 24,25(OH)2D were not changed by PTE in any of the subjects or patients. The results provide evidence that hypocalcemia in HP and PHP arises in part from low circulating la,25-(OH)2D, and indicate that the lack of change in serum la,25(OH)2D with PTE in patients with PHP is related to impaired renal adenylate cyclase and phosphaturic responses. These and previous results support the idea that diminished renal production of la,25(OH)2D, because of a defect in the parathyroid hormone-responsive adenylate cyclase system, may be a contributing factor in the pathogenesis of the abnormal calcium metabolism in PHP.
INTRODUCTION
The metabolic defect that accounts for the kidney's lack of response to parathyroid hormone (PTH)l in pseudohypoparathyroidism (PHP) was attributed to an abnormal adenylate cyclase system in the renal tubule (1, 2) . Thus, PTH and parathyroid extract (PTE) consistently increase urinary cyclic AMP and phosphate in normal subjects and in patients with hypoparathyroidism (HP), but not in patients with PHP (1) (2) (3) .
Available evidence also indicates that there is a defect in the renal production of la,25-dihydroxyvitamin D (la, 25 [OH]2D) in PHP, which causes impaired in- ' Abbreviations used in this paper: HP, hypoparathyroidism; 25 -OHD, 25-hydroxyvitamin D; la,25(OH)2D, la,25-dihydroxyvitamin D; la,25(0H)2D3, la,25-dihydroxyvitamin D3; 24,25(OH)2D, 24,25-dihydroxyvitamin D; PHP, pseudohypoparathyroidism; PTE, parathyroid extract; PTH, parathyroid hormone.
testinal absorption of calcium, hypocalcemia, and secondary hyperparathyroidism (4) (5) (6) (7) . These abnormalities are reversed by treatment with small doses of la,25-dihydroxyvitamin D3 (1a, 25 [OH]2D3) (4, (6) (7) (8) . Previous studies showed that PTE readily increases the serum calcium in normal subjects and in patients with HP, but not in those with PHP (2, 3, 5, 9, 10) . This abnormal response was attributed to an associated defect in the adenylate cyclase system in the skeleton (1, 2) .
The present studies were carried out to compare the effects of PTE on serum la,25(OH)2D in normal subjects, in patients with HP, and in patients with PHP. The results indicate that PTE readily increases serum la,25(OH)2D in normals and in patients with HP, but not in those with PHP.
METHODS
Two normal subjects-a man and a woman-two patients with HP, and six patients with PHP were hospitalized at the Clinical Research Center of the Indiana University Medical School, Indianapolis, Ind. They were given a constant daily diet and fluid intake, and distilled water to drink. The diets were estimated to contain 400 and 900 mg/d of calcium and phosphorus, respectively. Daily fasting blood samples were obtained for determination of serum calcium, phosphorus, 25 -hydroxyvitamin D (25-OHD), 24,25-dihydroxyvitamin D (24, 25 [OH]2D), and la,25(OH)2D. 24-h urines were obtained for measurement of calcium and phosphorus. Serum ancl urinary calcium (11) and phosphorus (12) were analyzed by methods modified for the Auto Analyzer. Serum PTH was measured by radioimmunoassay with antiserum (chicken 9, kindly provided by Dr. Eduardo Slatopolsky, St. Louis, Mo.) which is predominantly directed against the carboxylterminal portion of the hormone and which was used at a final concentration of 1:20,000 as previously described (13) . The normal range is 0.55 ng/ml or less, and serum PTH can be detected in 85% of normal subjects. Urinary cyclic AMP was determined by the method of Gilman (14) as previously described (2) . Serum 25-OHD, 24,25(OH)2D, and la,25(OH)2D were measured by methods previously reported (15, 16) . Serum (3-4 ml) was extracted with methanol-methylene chloride (2:1, vol/vol). The extract was fractionated by chromatography on a Sephadex LH 20 column (0.9 x 15 cm) in the solvent system n-hexane:chloroform:methanol (9 82%, respectively. The intra-and interassay variations were 12% or less. Detection limit for the two assays was 0.1 ng/ assay tube. Mean values for 25-OHD and 24,25(OH)2D in normal sera were 27.7+6.4 (n = 95, +SD) and 1.4+±0.6 ng/ml (n = 85), respectively. 95% confidence values were 14.9-40.5 ng/ml for 25-OHD and 0.8-2.0 ng/ml for 24,25(OH)2D. Serum la,25(OH)2D was measured by chick cytosol receptor assay employing an intestinal mucosal cytosol receptor from rachitic chicks, a Tris-HCL, KCL, thioglycerol-glycerol buffer system, and dextran-charcoal-human plasma separation of bound from free 1,25(OH)2D as previously described (15, 16 (15) .
Parathyroid extract (Eli Lilly and Co., Indianapolis, Ind.) was given by intramuscular injection every 12 h. Except where noted, the dose was 3 U/kg body wt. la,25(OH)2D3 (Hoffman-LaRoche) was given as a single morning dose.
Correlation coefficient and statistical analysis of paired and nonpaired data by t test were calculated with a Hewlett-Packard calculator, model 9815A (Hewlett-Packard Co., Palo Alto, Calif.). Correlation coefficient and the test for significance between two regressions were determined by standard methods (17) .
RESULTS
The clinical findings in the normal subjects and patients are summarized in Table I . Serum PTH was undetectable in the patients with HP, and was abnormally elevated in the patients with HP who were on no treatment or received inadequate doses of vitamin D.
The effects of PTE in two normal subjects are shown in Fig. 1 . PTE (days [5] [6] [7] [8] (Table II) .
The effects ofPTE in two patients with HP are shown in Fig. 2 . During an initial control period (days [1] [2] [3] [4] , serum calcium and serum la,25(OH)2D were abnormally low in patient A, who was on no treatment, and were at the lower range of normal in patient B, who was receiving 50,000 U of vitamin D every other day. PTE (days [5] [6] [7] [8] increased serum calcium and serum la,25(OH)2D, lowered serum phosphorus, and increased urinary calcium, phosphorus, and cyclic AMP. Mean serum 25-OHD and serum 24,25(OH)2D, which initially were within the normal range in patient A and were strikingly elevated in patient B, were not altered by PTE (Table III) .
The effects of PTE in four patients with PHP are shown in Fig. 3 . During an initial control period (days 1-4), serum calcium was abnormally low in each of the patients, and serum la,25(OH)2D was abnormally low in three of them. Serum phosphorus was increased in three of them. In contrast to the response in normals and patients with HP, PTE (days [5] [6] [7] [8] produced little or no change in both serum and urinary calcium and phosphorus, serum la,25(OH)2D, and urinary cyclic AMP in the patients with PHP. Initially, mean serum 25-OHD and 24,25(OH)2D were increased in patient C, who was receiving 100,000 U a day of vitamin D, and were normal in the other patients. They were not altered by PTE (Table II) . The effects of PTE in two patients with PHP who were on chronic treatment with la,25(OH)2D3 are shown in Fig. 4 . During an initial control period (days 1-4), serum calcium was at the lower range of normal and serum la,25(OH)2D was abnormally low in both patients. PTE produced only slight increases in serum la,25(OH)2D in each of them. There was an increase in serum calcium in patient H, but not in patient G. Mean serum 25-OHD and serum 24,25(OH)2D were within the normal range in both patients and were not altered by PTE (Table II) .
There were highly significant negative correlations between the serum phosphorus and serum la,25-(OH)2D in the normals, in patients with HP (Fig. 5) , and in the patients with PHP (Fig. 6) . Values for two adults with PHP (patients D and E) fell along the same axis as that of the normals and patients with HP, whereas values for two adolescents (patients C and F) fell along a separate axis. There was a significant difference among the slopes of the regression of the adolescents with PHP, that of the normals and patients with HP (P < 0.05), and that of the adults with PHP (P < 0.01). The last two slopes of the regressions were not significantly different from each other.
There were significant positive correlations between serum la,25(OH)2D and serum calcium in the normals and patients with HP ( Fig. 7) , and those in the patients with PHP (Fig. 8 ). There was a statistically significant difference between the slopes of the regressions of the two groups (P < 0.01).
In individual patients, there were significant negative correlations between serum phosphorus and serum la,25(OH)2D, and significant positive correlations between serum la,25(OH)2D and serum calcium in each of the normals and patients with HP (Table III) . In contrast, there were significant correlations in only one of the patients with PHP.
In all the studies, there was a significant correlation between mean serum 25-OHD and mean serum 24,25(OH)2D(r = 0.962, P < 0.01).
DISCUSSION
Our results confirm that there are low values for serum la,25(OH)2D in HP (18) and PHP (5) (6) (7) 18 Results are given asn mean±SE. PTE, 3 U/kg body wt i.m. every 12 h. * On treatment with vitamin D2 (see Table I ).
On treatment with la,25(OH)2D3 (see Table I ). tween the serum la,25(OH)2D and serum phosphorus. It is known that serum la,25(OH)2D, serum phosphorus, and serum growth hormone are normally increased during adolescence (21) (22) (23) (24) , and that growth hormone increases the phosphorus tubular maximum for reabsorption by the kidney (Tm) (22, 23) . However, recent evidence indicates that growth hormone does not alter circulating la,25(OH)2D (24) . These results provide evidence that the increase in serum la,-25(OH)2D during adolescence is not mediated by growth hormone and must result from some other mechanism. An investigation carried out with kidney tissue from a patient with PHP showed a high Km for ATP and decreased adenylate cyclase activity in response to PTH at subsaturating concentrations of ATP (25) . The abnormality could be entirely corrected by GTP. In this patient, a defect in the nucleotide receptor or concentration of the nucleotide may have caused an abnormality in the PTH-responsive adenylate cyclase system in renal cortex. 4 Effects of PTE, 6 U/kg body wt per day, on serum and urinary calcium (Ca) and phosphorus (P), serum la,25(OH)2D, and urinary cyclic AMP in two patients with pseudohypoparathyroidism on chronic treatment with la,25(OH)2D3. The dose of PTE was 3 U/kg body wt per day on days 5-7 in patient H.
in erythrocytes of patients with PHP and skeletal abnormalities, but not in those patients with PHP and a normal skeleton (26) . This raises the possibility of a generalized defect in the adenylate cyclase system, including the skeleton, which might account for hypocalcemia and the lack of calcemic response to PTE in this group of patients.
Our findings demonstrate that PTE consistently increased the serum calcium in normal subjects and patients with HP, but produced little or only modest change in serum calcium in the patients with PHP who were not being treated with 1a,25(OH)2D3. As noted before, this lack ofresponse ofthe serum calcium to PTE is characteristic of PHP (2, 3, 5, 9, 10) . A number of possible mechanisms might be responsible. Refractoriness of the skeletal system may occur because of secondary hyperparathyroidism, because of deficiency of la,25(OH)2D (4-6, 27), because of a lack of increase in circulating la,25(OH)2D as shown in the present findings, because of a defect in the skeletal adenylate cyclase system similar to that in the kidney (1, 2), or because an abnormal form of PTH is produced, which occupies but does not activate receptors in target organs (28) .
Available evidence indicates that refractoriness of bone to PTH develops after exposure to the hormone. The cyclic AMP response of rat calvaria to PTH and prostaglandin El is abolished by exposure for 60 min to PTH and prostaglandin El, respectively (29) . Similarly, isolated bone cells from mouse calvaria are down regulated by exposure to PTH (30) .
There is both clinical and experimental evidence that deficiency of vitamin D or its metabolites impairs the calcemic response to PTH. In the vitamin D-deficient rat, this defect is corrected within 24 h by a single dose of vitamin D (31) . Vitamin D deficiency, however, does not alter PTH-stimulated adenylate cyclase activity or accumulation of cyclic AMP in rat calvaria (31) . Thus, the lack of response to PTH is not related to an abnormal adenylate cyclase system. An attenuated response to PTE also occurs in chronic renal failure. In uremic thyroparathyroidectomized dogs, this abnormal response is restored by treatment with la,25-(OH)2D3 and 24,25(OH)2D3 (32 (32) . In uremia, the abnormal calcemic response is apparently related to deficiency of these metabolites of vitamin D. Clinically, hypercalcemia does not occur in primary hyperparathyroidism when there is vitamin D deficiency until after the vitamin deficiency is corrected (33, 34) . Further, isolated la,25(OH)2D deficiency was reported to cause skeletal resistance to PTH in a patient with hypocalcemia and secondary hyperparathyroidism caused by low serum la,25(OH)2D (27) . The impaired calcemic response was corrected by treatment with 1a,25(OH)2D, 1 ,ug/d for 4 d. The patient initially showed a normal increase in urinary cyclic AMP and phosphorus in response to PTE and therefore did not have the classic form of PHP. It should be noted that chronic treatment with 1a,25(OH)2D3 improved the skeletal response to PTE in one of our patients with PHP.
It can be argued that changes in 1a,25(OH)2D may contribute to the calcemic effects of PTE. 1a,25-(OH)2D is normally a major determinant of fractional intestinal absorption of calcium or a (35, 36) and increases the skeletal release of calcium in a dose-dependent fashion (37) . Serum la,25(OH)2D, serum calcium, and a are increased in patients with primary hyperparathyroidism (35, 38) and return to normal after surgical treatment (38) . On the other hand, serum Ia,-25(OH)2D, serum calcium, and intestinal absorption of calcium are low in HP (16, 18) and PHP (4-7), and hypocalcemia and impaired intestinal absorption ofcalcium can be treated in these disorders with small doses of la,25(OH)2D3 (4, 6-8, 39, 40) . In addition, our studies showed parallel changes in serum la,25-(OH)2D and serum calcium before, during, and after PTE in the normals and patients with HP. There were significant positive correlations between the serum calcium and serum la,25(OH)2D, both collectively and in the individual studies.
PTE produced very little change in serum la,25-(OH)2D in our patients with PHP. The lack of change may be a contributing factor to the lack of calcemic response to PTE. In support of this hypothesis is the report that PTE produced transient increases in serum 1a,25(OH)2D and serum calcium in a patient with PHP that were similar to those seen in our normal subjects and patients with HP (41) . As in our studies, the changes in serum la,25(OH)2D and serum calcium before, during, and after PTE occurred in parallel.
Serum 1a,25(OH)2D remained low and changed very little in response to PTE in both of the patients with PHP who were being treated with the metabolite.
The low values during treatment with la,25(OH)2D3, which were observed previously (7) , are attributed to the short half-life of the metabolite (42), which was given as a single morning dose.
The mechanism for the lack of calcemic response to PTE during treatment with la,25(OH)2D3 in one of our patients is not clear. Variability in serum la,25(OH)2D during the day after the single morning dose or lack of increase in serum concentration ofthe metabolite in response to PTE could be responsible. Before treatment, a bone biopsy showed increases in osteoclasts, 2.40/ mm2 (normal range: 0.22-0.80), trabecular osteoclastic resorptive surface, 23.9% (normal range: 2.5-4.7%) and periosteocytic lacunae, 63.9 Am2 (normal range: 45.2-56.2 /Im2) as previously reported (6) . These findings indicate excess circulating parathyroid hormone. It is difficult in the case of this patient, therefore, to attribute the abnormal calcemic response entirely to an abnormal adenylate cyclase system in the skeleton.
The possibility that a biologically inactive form of PTH (28) is regularly produced in PHP is unlikely. Several cases have been reported in which there was clinically apparent osteitis fibrosa cystica (10, 43) . In one of them, an increase in urinary excretion of biologically active PTH was demonstrated (10) . As already noted, changes in quantitative bone histology, increases in trabecular osteoclastic resorptive surface, and periosteocytic lacunae, which occur in PHP as a consequence of secondary hyperparathyroidism, are similar to the changes that are observed in primary hyperparathyroidism (5, 6) . The same argument may be used to refute the concept for an abnormal skeletal adenylate cyclase system in PHP (1, 2). As noted already, some patients with PHP may have a deficiency in the nucleotide regulatory protein (26) . This could produce a partial defect that would allow morphologic changes in response to PTH but still impair mobilization of calcium from the skelton.
In summary, we attribute the attenuated calcemic response to PTE in PHP to a combination of several factors: deficiency of la,25(OH)2D, lack of change in serum la,25(OH)2D, possible down regulation of the skeleton because of secondary hyperparathyroidism, and a putative defect in the adenylate cyclase system in the skeletal system (1, 2). In our view the production of an abnormal form of PTH (28) (44) . It was reported that serum 24,25(OH)2D is increased in primary hyperparathyroidism (45) . It appears that the effects of PTE are predominant in otir accute studies, whereas the effects of hypercaleemia and increases in serum la,25(OH)2D (16, 18, 19) are predominant in the patients with primary hyperparathyroidism. The positive correlation letween serum 25-OHD and serum 24,25-(OH)2D was reported previouisly (46) .
